NATCOPHARM

Natco Pharma Share Price

 

 

Invest in Natco Pharma with 3.04X leverage

Invest with MTF

Performance

  • Low
  • ₹906
  • High
  • ₹921
  • 52 Week Low
  • ₹727
  • 52 Week High
  • ₹1,420
  • Open Price₹921
  • Previous Close₹916
  • Volume283,088

Investment Returns

  • Over 1 Month -2.04%
  • Over 3 Month + 10.69%
  • Over 6 Month + 4.29%
  • Over 1 Year -33.31%

Smart Investing Starts Here Start SIP with Natco Pharma for Steady Growth!

Invest Now

Natco Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 10.6
  • PEG Ratio
  • -0.5
  • Market Cap Cr
  • 16,272
  • P/B Ratio
  • 1.9
  • Average True Range
  • 27.55
  • EPS
  • 85.91
  • Dividend Yield
  • 0.6
  • MACD Signal
  • 17.29
  • RSI
  • 53.13
  • MFI
  • 70.86

Natco Pharma Financials

Natco Pharma Technicals

EMA & SMA

Current Price
₹908.50
-7.75 (-0.85%)
pointer
  • Bearish Moving Average 7
  • Bullish Moving Average 9
  • 20 Day
  • ₹905.02
  • 50 Day
  • ₹881.81
  • 100 Day
  • ₹880.35
  • 200 Day
  • ₹918.94

Resistance and Support

911.87 Pivot Speed
  • R3 932.23
  • R2 926.57
  • R1 917.53
  • S1 902.83
  • S2 897.17
  • S3 888.13

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

NATCO Pharma Ltd. is a leading Indian pharmaceutical company specializing in generic and specialty medicines, including oncology, cardiology, and central nervous system therapies. It serves global markets with a focus on affordable and high-quality healthcare solutions.

Natco Pharma has an operating revenue of Rs. 4,387.70 Cr. on a trailing 12-month basis. An annual revenue growth of 16% is outstanding, Pre-tax margin of 52% is great, ROE of 24% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 6% and 5% from 50DMA and 200DMA. It is currently FORMING a base in its weekly chart and is trading around 13% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 56 which is a POOR score indicating inconsistency in earnings, a RS Rating of 62 which is FAIR indicating the recent price performance, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 74 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Natco Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-14 Quarterly Results & Interim Dividend
2025-08-12 Quarterly Results & Interim Dividend
2025-05-28 Audited Results
2025-02-12 Quarterly Results & Interim Dividend
2024-11-12 Quarterly Results & Interim Dividend
Date Purpose Remarks
2025-11-20 INTERIM Rs.1.50 per share(75%)Second Interim Dividend
2025-08-19 INTERIM Rs.2.00 per share(100%)Interim Dividend
2025-02-18 INTERIM Rs.1.50 per share(75%)Third Interim Dividend
2024-11-27 INTERIM Rs.1.50 per share(75%)Second Interim Dividend (RD & XD dates revised)
2024-08-23 INTERIM Rs.3.00 per share(150%)Interim Dividend
View Natco Pharma Dividend History Arrow

Natco Pharma F&O

Natco Pharma Shareholding Pattern

49.48%
2.2%
3.31%
14.09%
0%
25.84%
5.08%

About Natco Pharma

Natco Pharma Ltd. is leading pharmaceutical company in India, specializing in production of generic medicines, bulk drugs, & specialty pharmaceuticals. Founded in 1981, Natco has established itself as key player in global pharmaceutical industry, with strong focus on oncology, cardiology, & gastroenterology segments. company operates state of the art manufacturing facilities that comply with global regulatory standards, ensuring production of high quality medicines. Natco Pharma is known for its innovation, particularly in development of affordable generic versions of high cost drugs, which has made it preferred partner for healthcare providers worldwide.

NATCO Pharma Limited (NATCO) is pharmaceutical firm that focuses on research & development & is vertically integrated. Its core competencies include creating, producing, & selling complicated pharmaceuticals for specific therapeutic areas. NATCO is now present in three business categories of contract manufacturing business, active pharmaceutical ingredients (APIs), & final dosage formulations (FDF).
 

View More
  • NSE Symbol
  • NATCOPHARM
  • BSE Symbol
  • 524816
  • Chairman & Managing Director
  • Mr. V C Nannapaneni
  • ISIN
  • INE987B01026

Similar Stocks to Natco Pharma

Natco Pharma FAQs

Natco Pharma share price is ₹908 As on 27 December, 2025 | 19:11

The Market Cap of Natco Pharma is ₹16272.1 Cr As on 27 December, 2025 | 19:11

The P/E ratio of Natco Pharma is 10.6 As on 27 December, 2025 | 19:11

The PB ratio of Natco Pharma is 1.9 As on 27 December, 2025 | 19:11

Evaluate company's performance in pharmaceutical industry & its product pipeline before investing
 

Key metrics include revenue growth, product approvals, & profit margins.

Open Demat account with 5 Paisa Capital & post doing KYC & active account search for Natco Pharma share, you can then put order as you prefer.

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23